Exploring New Frontiers in Automated Insulin Delivery at EASD 2026

Unveiling the Future of Diabetes Management at EASD 2026

The European Association for the Study of Diabetes (EASD) conference in Milan showcased groundbreaking developments in diabetes management, spearheaded by SiBionics. On October 5, 2026, the company unveiled its ambitious program titled "See More, Act Sooner," aiming to synergize continuous glucose monitoring with advanced treatment protocols.

A Vision for Comprehensive Diabetes Care

The presentation outlined three pivotal themes: "See More - Not Just Glucose," which emphasizes a comprehensive approach to monitoring glucose and ketones; "Act Sooner - From Insight to Intervention," focusing on multi-modal sensing and insulin delivery; and "Go Further - Making the Unimaginable Possible," which explores the potential of biosensing technologies in diabetes management.

The complexity of diabetes care necessitates a tailored approach that integrates various monitoring modalities. The symposium featured expert discussions, including Professor Mark Evans from the University of Cambridge and Dr. Guido Freckmann from Germany’s Institute for Diabetes Technology. They examined the evolution of diabetes treatment technologies and patient-centered care.

Continued Glucose Monitoring and Individualized Support

One of the highlights of the symposium was a discussion led by Professor Karolina Kędzierska-Kapuza on Continuous Glucose Monitoring (CGM) and personalized care for Type 3c diabetes patients. Additionally, Professor Wei Qiang presented insights into CGM accuracy and emerging concepts in multi-modal sensing technologies, while Professor Andrej Janež focused on continuous ketone monitoring in the GLP-1 treatment era.

The SMART02 Study: Innovations in Insulin Delivery

Central to the discussion was the SMART02 study, which evaluated the early prototype of the niia signature device. This innovative tool, developed collaboratively by SiBionics and PharmaSens since their partnership began in June 2025, seeks to streamline insulin delivery by integrating CGM, insulin delivery, and automated glucose control algorithms into a single patch.

The study aimed to address the crucial integration challenge of maintaining glucose measurement accuracy while administering insulin close to the sensor. Initial findings revealed that significant disruptions post-bolus were rare, occurring mainly with boluses of 10 units or more (20-25% probability). Notably, sensor signals typically regained stability approximately 20 minutes after bolus delivery.

In the second phase of the study, the niia prototype, in conjunction with an automated insulin delivery algorithm developed by Professor Ahmad Haidar, produced stable results throughout the test period. These findings are a promising step forward in streamlining diabetes management technologies.

Bridging Clinical Needs and Technology

Combined, the exhibition and symposium highlighted the intersection of clinical needs with cutting-edge technological innovations. SiBionics and PharmaSens are committed to exploring how the niia signature can facilitate the adoption and usability of automated insulin delivery systems in everyday life. Further research is essential to establish its clinical effectiveness and potential impact.

It's important to note that the niia signature is currently in the clinical trial phase and has not been approved or cleared for use in any market.

About SiBionics and PharmaSens

Founded in 2015 and based in Shenzhen, SiBionics is a medical technology firm specializing in CGM and integrated health solutions, employing nearly 700 professionals worldwide. They develop reliable solutions for chronic conditions by combining advanced sensor technologies with AI-driven algorithms, providing real-time data to support healthcare decision-making.

PharmaSens AG, a private Swiss company, is dedicated to simplifying diabetes treatment and expanding the accessibility of pump therapies. They are recognized for their extensive expertise in diabetes treatment and medical device engineering, contributing to various generations of insulin pumps.

For more information on SiBionics, visit SiBionics CGM. To learn more about PharmaSens's innovations, check PharmaSens.